Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients

Karamouzian, Saeid; Nematollahi-Mahani, Seyed Noureddin; Nakhaee, Nouzar; Eskandary, Hossein

doi:10.1016/j.clineuro.2012.02.003

Cited by 151 publications

(112 citation statements)

References 36 publications

(71 reference statements)

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Since 2005, a number of clinical trials have evaluated the safety and efficacy of autologous bone marrow cell transplantation in acute and chronic SCI patients (Deda et al, 2008;Geffner et al, 2008;Jarocha et al, 2014;Karamouzian et al, 2012;Park et al, 2005;Sykova et al, 2006;Yoon et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients

Xiao

Tang

et al. 2016

Sci. China Life Sci.

View full text Add to dashboard Cite

The objective of this clinical study was to assess the safety and feasibility of the collagen scaffold, NeuroRegen scaffold, one year after scar tissue resection and implantation. Scar tissue is a physical and chemical barrier that prevents neural regeneration. However, identification of scar tissue is still a major challenge. In this study, the nerve electrophysiology method was used to distinguish scar tissue from normal neural tissue, and then different lengths of scars ranging from 0.5-4.5 cm were surgically resected in five complete chronic spinal cord injury (SCI) patients. The NeuroRegen scaffold along with autologous bone marrow mononuclear cells (BMMCs), which have been proven to promote neural regeneration and SCI recovery in animal models, were transplanted into the gap in the spinal cord following scar tissue resection. No obvious adverse effects related to scar resection or NeuroRegen scaffold transplantation were observed immediately after surgery or at the 12-month follow-up. In addition, patients showed partially autonomic nervous function improvement, and the recovery of somatosensory evoked potentials (SSEP) from the lower limbs was also detected. The results indicate that scar resection and NeuroRegen scaffold transplantation could be a promising clinical approach to treating SCI.NeuroRegen scaffold, chronic spinal cord injury, scar resection, collagen scaffold transplantation, bone marrow mononuclear cells, tissue regeneration Citation:Xiao, Z., Tang, F., Tang, J., Yang, H., Zhao, Y., Chen, B., Han, S., Wang, N., Li, X., Cheng, S., Han, G., Zhao, C., Yang, X., Chen, Y., Shi, Q., Hou, S., Zhang, S., and Dai, J. (2016). One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients. Sci China Life Sci 59, 647 -655.

show abstract

Section: Introductionmentioning

confidence: 99%

One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients

Xiao

Tang

et al. 2016

Sci. China Life Sci.

View full text Add to dashboard Cite

show abstract

“…Recent studies however have elucidated their heterogeneity and the changes exhibited by these cells following SCI, thereby underscoring the need to preserve their normal physiological functions. Studies mentioned above, as well as other studies that are not detailed here, are indicative of the growing appreciation of cell transplantation therapies for therapeutically targeting astrocytes in SCI.With a special focus on chronic SCI conditions, many clinical trials based on the transplantation of unmodified mesenchymal, neural or bone-marrow stem cells have been launched around the world [167][168][169][170][171] . Among phase 1 studies, most of them have focused on safety measurements and graft survival according to different routes of administration (mostly intrathecal…”

mentioning

confidence: 99%

Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury

Nicaise

Mitrečić

Falnikar

et al. 2015

WJSC

View full text Add to dashboard Cite

in experimental ALS and SCI models and we discuss avenues for future directions based on latest molecular findings regarding astrocyte biology. Core tip: Amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI) result in incurable neurological dysfunction due to loss of spinal motor neurons and axonal degeneration, amongst other mechanisms. Astrocytes are increasingly recognized as being necessary for neuroprotection and regeneration in the central nervous system as they promote axonal growth and deliver essential neurotrophic factors under both physiological and pathophysiological conditions. Given the central role played by astrocytes, we gathered convincing results from ALS and SCI literature that argue in favor of stem cell-based astrocyte replacement therapies and stress the scientific community to investigate more deeply the molecular understanding of astrocyte biology. MULTIPLE FACETS OF ASTROCYTES IN THE CENTRAL NERVOUS SYSTEM Astrocyte functionsAstrocytes are the most abundant cells in the central nervous system (CNS), outnumbering neuronal cells by several fold in some CNS regions. They have long been relegated to a secondary position, behind neurons or oligodendrocytes, as many thought that astrocytes were barely by-standers of the CNS. Accounting for a large fraction of the brain volume, their particular shape and tissue distribution are known to elaborate an extensive network of fine interconnected processes. Their star-shaped morphology projecting long branched processes provides a large coverage of CNS structures and the ensheathment of the brain or spinal cord in the pia matter. They draw the whole brain microanatomy by secreting astrocyte-derived extracellular matrix proteins (e.g., chondroitin sulfate proteoglycans, hyaluronan, tenascin proteins family, thrombospondin), thereby providing structural support for nervous system cells. Beside their structural role, astrocytes are recognized to fulfill and support many, if not all, functions of the healthy CNS [1] . Astrocyte endfeet cover more than 90% of the CNS vasculature and come in contact with endothelial cells. Expressing key glucose transporter-1, astrocytes convoy glucose from blood vessels to nervous system cells, most of them being devoid of direct access to this high-end source of energy. Hence, astrocytes synthetize via specific metabolic pathways glycogen and lactate, main energy fuels for neurons or distant synapses. Through humoral factors released at the perivascular space, astrocytes control local cerebral blood flow and bloodbrain barrier (BBB) integrity. Transforming growth factor-beta, glial-derived neurotrophic factor (GDNF), fibroblast growth factor 2 (FGF2) and angiopoietin 1 (binding the endothelium-specific receptor TIE2), all secreted at the vascular end-feet, act on endothelial cells in order to induce or maintain an operational BBB [2,3] . Astrocytes-released growth factors [e.g., brainderived neurotrophic factor, BDNF; ciliary neurotrophic factor (CNTF)] exert beneficial effects far beyond the perivascular spa...

show abstract

“…Several studies have reported sensory and motor improvements after 1-3 mo of stem cell transplantations combined with various other cells and growth factors [117][118][119][120][121] . In contrast, Karamouzian et al [122] stated that despite the feasibility and safety of cellular transplantations, the improvements in terms of functional recovery were not statistically significant in their study [122] . The low numbers of patients in these studies make it difficult to provide a definitive statement on the clinical potential of stem cell transplantation for SCI.…”

Section: Spinal Cord Injurymentioning

confidence: 63%

Stem cells for spine surgery

Schroeder

Kueper

Kaplan

et al. 2015

WJSC

View full text Add to dashboard Cite

In the past few years, stem cells have become the focus of research by regenerative medicine professionals and tissue engineers. Embryonic stem cells, although capable of differentiating into cell lineages of all three germ layers, are limited in their utilization due to ethical issues. In contrast, the autologous harvest and subsequent transplantation of adult stem cells from bone marrow, adipose tissue or blood have been experimentally utilized in the treatment of a wide variety of diseases ranging from myocardial infarction to Alzheimer's disease. The physiologic consequences of stem cell transplantation and its impact on functional recovery have been studied in countless animal models and select clinical trials. Unfortunately, the bench to bedside translation of this research has been slow. Nonetheless, stem cell therapy has received the attention of spinal surgeons due to its potential benefits in the treatment of neural damage, muscle trauma, disk degeneration and its potential contribution to bone fusion.

show abstract

Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients

Cited by 151 publications

References 36 publications

One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients

One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients

Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury

Stem cells for spine surgery

Contact Info

Product

Resources

About